Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's ...
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the secon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback